Showing 3171-3180 of 5610 results for "".
- Research Firm Executive Explains Optimistic Market Forecasthttps://reachmd.com/news/research-firm-executive-explains-optimistic-market-forecast/2475344/The research firm Clarivate projected the global aesthetics market to reach a value of €22.9 billion by 2028, growing at a compound annual growth rate (CAGR) of nearly 8%. This growth, Clarivate said, is driven by trends such as the shift toward natural-looking treatments, the rise of combination
- Pulmonary Arterial Hypertension: Evaluating a Novel Drug Treatmenthttps://reachmd.com/news/pulmonary-arterial-hypertension-evaluating-a-novel-drug-treatment/2474022/Pulmonary arterial hypertension (PAH) is a progressive and life-limiting condition characterized by the narrowing of small pulmonary arteries, which increases pulmonary vascular resistance and places a
- Unveiling the Impact of SinergiAPS: Patient Feedback as a Catalyst for Safer Primary Carehttps://reachmd.com/news/unveiling-the-impact-of-sinergiaps-patient-feedback-as-a-catalyst-for-safer-primary-care/2473992/Patient safety in primary care remains a persistent challenge, often compounded by the fast pace and fragmented nature of outpatient clinical encounters. Yet, a growing body of evidence suggests that the patient perspective—often overlooked—can provide a critical v
- COVID-19: Emergence and Implications of the LP.8.1 Varianthttps://reachmd.com/news/covid-19-emergence-and-implications-of-the-lp81-variant/2473945/Understanding the Emergence of the LP.8.1 Variant The global healthcare landscape continues to grapple with the evolving nature of SARS-CoV-2, marked by the emergen
- Female Hormones: Mediators of Immune-Derived Pain Suppressionhttps://reachmd.com/news/female-hormones-mediators-of-immune-derived-pain-suppression/2473954/Innovative studies at UC San Francisco have uncovered an intriguing mechanism: female hormones stimulate immune cells in the meninges surrounding the spinal cord, leading to the release of enkephalin, a natural opioid. This discovery enhances our understanding of t
- Gastric Bypass: Clinical Efficacy and Cost Efficiency for Severe Obesityhttps://reachmd.com/news/gastric-bypass-clinical-efficacy-and-cost-efficiency-for-severe-obesity/2473920/In a development poised to reshape obesity treatment protocols, a landmark study funded by the National Institute for Health and Care
- SOX9 and Its Role in Prognostication of Gastric Adenocarcinomahttps://reachmd.com/news/sox9-and-its-role-in-prognostication-of-gastric-adenocarcinoma/2473898/Gastric cancer frequently reaches an advanced stage before detection due to its asymptomatic nature in the early phases. Recent findings on SOX9 expression provide a promising avenue for enhancing prognostic evaluations and shaping treatment protocols.
- Prox1 Identified as Molecular Brake on Retinal Repair in Mammalshttps://reachmd.com/news/prox1-identified-as-molecular-brake-on-retinal-repair-in-mammals/2473907/Researchers have uncovered a powerful molecular barrier preventing mammals from regrowing damaged retinal neurons—an ability long considered exclusive to species like zebrafish. The culprit? A homeobox transcription factor called Prox1. Published in Nature Communications, the stud
- Pemphigus Management: Rituximab Use and Early Relapse Predictorshttps://reachmd.com/news/pemphigus-management-rituximab-use-and-early-relapse-predictors/2474230/Pemphigus, known for its autoimmune blistering nature, presents substantial treatment challenges due to its intricate pathophysiology. In dermatology, where precision and personalized care are paramount, recent findings have fostered the development of innovative p
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://reachmd.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up